Osteoarthritis Therapeutics: Global Markets

Osteoarthritis Therapeutics: Global Markets

Report Scope:

This report provides a detailed description of the approaches used to treat pain management associated with osteoarthritis and the latest updates in the market. The report includes market estimates for different types of drugs and therapies used to treat osteoarthritis.

Based on anatomy, the osteoarthritis therapeutics market is segmented into knee osteoarthritis, hip osteoarthritis, others (shoulder, hand and small joint osteoarthritis).

Based on drug type, the osteoarthritis therapeutics market is segmented as viscosupplementation agents; Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including ibuprofen, aspirin, diclofenac, naproxen, and other NSAIDs; analgesics; and corticosteroids.

Based on route of administration, the osteoarthritis therapeutics market is segmented into parenteral route, oral route and topical route.

Based on drug classification, the osteoarthritis therapeutics market is segmented into prescription drugs and over-the-counter (OTC) drugs.

The report discusses the qualitative and quantitative factors influencing market growth. Market drivers, restraints and opportunities are discussed in the report.

This report discusses some of the major drivers and restraints in the global osteoarthritis therapeutics market, as well as the competition and the key players’ strategies and performances. The discussion is focused on the major market players, trends in product launches, collaborations, and mergers and acquisitions. The report also includes company profiles of major vendors including company overview, key product offerings, financial statistics and recent developments. The report provides insights on market shares and upcoming regional demand for osteoarthritis therapeutics.

Some of the major market players discussed in the report are Sanofi S.A., Fidia Farmaceutici S.p.A, Seikagaku Corp., Anika Therapeutics Inc., Pfizer Inc. and GlaxoSmithKline PLC. For market estimates, data has been provided for 2020, which serves as the base year, with forecasts for 2021 through 2026. Estimated values used are based on manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes:

- 27 data tables and 33 additional tables
- An overview of the global market for osteoarthritis therapeutics
- Estimation of the market size and analyses of global market trends, with data from 2019 to 2020, estimates for 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the market potential for osteoarthritis therapeutics, based on type of anatomy, drug type, route of administration, purchasing pattern and region
- Discussion on recent developments of agents for the treatment of OA, which includes potential disease-modifying osteoarthritis drugs (DMOADs) and novel therapeutics for pain relief
- Description of pharmacological and non-pharmacological methods of OA management and information on personalized medicines for OA
- Discussion on the risk of adverse cardiovascular events related to the use of NSAIDs in osteoarthritis
- Coverage of clinical trials and applications of attractive drugs in preclinical research; regulatory scenarios, ongoing research on anti-NGF therapy and government expenditures
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast, and assessment of new developments in the industry
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Comprehensive company profiles of the leading players, including Abbott Laboratories Inc., Bayer AG, Eli Lilly and Co., GlaxoSmithKline PLC, Pfizer Inc. and Sanofi.

Companies Mentioned

ABBOTT LABORATORIES
ANIKA THERAPEUTICS INC.
BAYER AG
BIOVENTUS
ELI LILLY AND CO.
FERRING B.V.
FIDIA FARMACEUTICI S.P.A.
FLEXION THERAPEUTICS INC.
GLAXOSMITHKLINE PLC
HORIZON THERAPEUTICS PLC
JOHNSON & JOHNSON INC.
NOVARTIS AG
PFIZER INC.
SANOFI
SEIKAGAKU CORP.